表紙
市場調査レポート

中国のインスリングラルギン市場の分析

Investigation Report on China Insulin Glargine Market, 2009-2018

発行 China Research and Intelligence 商品コード 296862
出版日 ページ情報 英文 40 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
中国のインスリングラルギン市場の分析 Investigation Report on China Insulin Glargine Market, 2009-2018
出版日: 2014年02月26日 ページ情報: 英文 40 Pages
概要

インスリングラルギン(Insulin glargine)は世界初の持効性インスリンアナログで、2000年に米国FDA・欧州医薬品庁の認証を獲得しました。中国では現在、9840万人もの患者を抱える世界最大の糖尿病市場となっており、経済・社会発展上の多大な負担となっています。また第二世代から第三世代のインスリンへの移行が始まりましたが、価格の高さなどから、ごく限られた範囲でしか普及していません。以上の様な状況を受けて、中国のインスリングラルギン市場は2005〜2012年に年平均(CAGR)70%以上もの急成長を遂げ、今後も更なる市場拡大が期待されています。

当レポートでは、中国におけるインスリングラルジン市場について分析し、中国国内での生産高および病院向け売上高・価格の動向(過去5年間分)、企業別・投薬形態別の市場シェア、主要メーカーのプロファイル、将来的な市場動向の見通し(今後5年間分)などを調査して、その結果を概略以下の構成でお届けします。

第1章 インスリングラルギンの関連概念

  • 症状
  • 世界市場での販売状況

第2章 中国のインスリングラルギン市場の概要

  • 特許の現状
  • 主要メーカー
  • 市場規模

第3章 インスリングラルギンの売上高の分析

  • 総売上高
  • 地域別の売上高

第4章 主要メーカーの市場シェアの分析

  • 市場シェア(金額ベース)
  • 市場シェア(数量ベース)

第5章 剤形別の市場規模の分析

  • 剤形別の市場シェア(金額ベース)
  • 剤形別の市場シェア(数量ベース)

第6章 インスリングラルギンの病院向け基準価格(企業別)

  • LANTUS(Aventis Behring GmbH製)の場合
  • Basalin(Gan & Lee Pharmaceuticals製)の場合

第7章 主要メーカーの分析

  • Aventis Behring GmbH
  • Gan & Lee Pharmaceuticals

第8章 中国のインスリングラルギン市場の将来展望

  • 糖尿病の発症率の傾向
  • 市場規模の予測
  • 市場パターンの予測
  • ジェネリック医薬品の研究状況

図表一覧

目次
Product Code: 1402114

With the improvement of people's living standard and changing of lifestyles, as well as deepening of the aging of society, prevalence rate of diabetes keeps rising, making it the third most threatening chronic disease to human health after tumor and cardiovascular disease. Its risk to disable or kill has become a heavy burden on individuals, families, society and governments.

According to statistics from IDF (International Diabetes Federation), the global prevalence rate of diabetes among adults aged 20 to 79 was 8.3% in 2013. The number of diabetes patients has reached 382 million, of which 80% are from medium- and low-income countries where it is still rising rapidly.

It is estimated that by 2035 there will be nearly 592 million people worldwide suffering from diabetes. In the evaluation of diabetes incidence and its trend among various countries and regions, China ranked the first with 98.4 million diabetes patients in 2013, followed by India (65.1 million), the U.S.A. (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that the number of diabetes patients in China will reach 143 million by 2035, which will still be the highest worldwide while that in the U.S.A. will merely reach 29.7 million. Rapid growth of diabetes in China and other developing countries has become an extraordinarily serious burden for these countries' social and economic development.

Insulin glargine is the first long-acting insulin analogue produced through recombinant DNA technology. It was approved for use by FDA (Food and Drug Administration) in April 2000 and EMEA (European Medicines Evaluation Agency) in June 2000. As there is no apparent peak in long-term use of insulin glargine, it has become the most widely used insulin in the United States.

In China, the third-generation insulin is under promotion. Because of the relatively high price, it is mainly used in first-tier cities at present. The second and third generation insulin will be faced with a market pattern of dislocation competition.

Based on CRI's research about certain sample hospitals in China, the CAGR (compound annual growth rate) of sales value of insulin glargine in Chinese sample hospital market exceeded 70% from 2005 to 2013. Human insulin is produced through genetic engineering methods, so a relatively high threshold of production technology is formed. Compared with other genetic engineering drugs, insulin is of large demand and comparatively cheap, so manufacturers have to attain an industrial production of large scale, low cost and mature technology before gaining profit. At present, Chinese market is mainly occupied by LANTUS produced by Aventis Behring GmbH and Basalin by Gan & Lee Pharmaceuticals. However, changes of global market pattern are expected to happen in the next few years. On the one hand, in the global market, MSD Co., Ltd. is working with Samsung Bioepis to develop LANTUS. The two companies declared on Feb 10, 2014 that the product will soon launch the third phase clinical trial on Type I and Type II diabetes. Presently, LANTUS generic drug produced by Eli Lilly and Company has come to the late-stage clinical trials. On the other hand, in Chinese market, some local businesses are also hastening the development of LANTUS generic drug.

As Chinese people's living standard improves and lifestyles change, incidence of diabetes continuously goes up, resulting in the year-after-year expanding of diabetes drug market in the country. According to CRI's investigation, total sales value of diabetes drug market in China surpassed CNY 18 billion in 2013. In China, the second-generation recombinant human insulin is still the market mainstream. However, as the third-generation insulin products are more technically advanced comparing with the second-generation by diminishing certain defects and shortening curing time effectively, it is expected to replace the second-generation in the near future. As a product with most growth potential among the three generations of insulin products in China, insulin glargine is expected to get more and more attention.

Through this report, the readers can acquire the following information:

  • Market Share of Major Insulin Glargine Manufacturers in Sample Hospitals in China
  • Sales Price of Insulin Glargine in Hospital Market in China
  • Major Insulin Glargine Enterprises in China
  • Market Share of Insulin Glargine by Dosage Form in Hospital Market in China

Prospect of China Insulin Glargine Market

The author recommends the report to the following:

  • Insulin Glargine API and Finished Product Manufacturers
  • Medical Institutions
  • Investors /Research Agencies Focusing on Insulin Glargine Market

Table of Contents

1. Relevant Concepts of Insulin Glargine

  • 1.1. Indication
  • 1.2. Sales Status on the Global Market

2. Market Overview of Insulin Glargine in China

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Investigation on Sales Value of Insulin Glargine in China, 2009-2013

  • 3.1. Total Sales Value
  • 3.2. Sales Value by Region

4. Investigation on Market Share of Major Insulin Glargine Manufacturers in China, 2009-2013

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Investigation on Market Size of Insulin Glargine by Dosage Form in China, 2009-2013

  • 5.1. Market Share by Sales Value and Dosage Form
  • 5.2. Market Share by Sales Volume and Dosage Form

6. Reference Price of Insulin Glargine in Hospital Market in China, 2013

  • 6.1. Insulin Glargine (LANTUS) Produced by Aventis Behring GmbH
  • 6.2. Insulin Glargine (Basalin) Produced by Gan & Lee Pharmaceuticals

7. Major Manufacturing Enterprises in China Insulin Glargine Market, 2009-2013

  • 7.1. Aventis Behring GmbH
  • 7.2. Gan & Lee Pharmaceuticals

8. Prospect of China Insulin Glargine Market, 2014-2018

  • 8.1. Trend of Diabetes Incidence
  • 8.2. Forecast on Market Size
  • 8.3. Forecast on Competition Pattern
  • 8.4. Generic Drugs in Research

Selected Charts

  • Chart Insulin Glargine Products Approved to Market in China, 2014
  • Chart Sales Value of Insulin Glargine in Global Market, 2009-2013
  • Chart Sales Value of Insulin Glargine in Hospital Market in China, 2009-2013
  • Chart Sales Value of Insulin Glargine by Region in China, 2009-2013
  • Chart Market Share of Insulin Glargine Enterprises by Sales Value in China, 2009-2013
  • Chart Forecast on Market Size of Hospital-used Insulin Glargine in China, 2014-2018
  • Chart Price of Insulin Glargine Produced by Aventis Behring GmbH in Hospital Market
  • Chart Price of Insulin Glargine Produced by Gan & Lee Pharmaceuticals in Hospital Market
Back to Top